Pluvicto-Induced 18F-PSMA PET Bone Flare

Clin Nucl Med. 2024 Feb 23. doi: 10.1097/RLU.0000000000005104. Online ahead of print.ABSTRACTA 79-year-old man with a history of metastatic prostate cancer was initially treated with Eligard and switched to relugolix in 2021. The 2022 bone scan presented superscan and extensive osseous metastatic lesions; some had intense PSMA uptake on the initial PSMA PET scan without nodal or visceral metastatic lesions. We treated him with Pluvicto and relugolix. The intermediate PSMA scan demonstrated prominent bone marrow PSMA uptake. However, PSA decreased 58.5%. We hypothesized that the patient might have a bone flare. The final PSMA scan confirmed our hypothesis. Based on our knowledge, this is the first case of Pluvicto-induced bone flare.PMID:38389206 | DOI:10.1097/RLU.0000000000005104
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research